Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21368935 | 0.89 | MAOB (0.51) | CHRM2CHRM1CHRM3TAAR1IDO1 | |
| SCHEMBL27549399 | 0.87 | CMA1 (0.56) | CHRM2CHRM1CHRM3TAAR1IDO1 | |
| SCHEMBL8305017 | 0.86 | TAAR1 (0.58) | CHRM2CHRM1CHRM3TAAR1IDO1 | |
| SCHEMBL3503547 | 0.84 | TAAR1 (0.56) | CHRM2CHRM1CHRM3TAAR1IDO1 | |
| SCHEMBL27610564 | 0.83 | IDO1 (0.56) | CHRM2CHRM1CHRM3TAAR1IDO1 | |
| SCHEMBL417948 | 0.83 | TAAR1 (0.61) | CHRM2CHRM1CHRM3TAAR1IDO1 | |
| SCHEMBL23617138 | 0.82 | TAAR1 (0.55) | CHRM2CHRM1CHRM3TAAR1IDO1 | |
| SCHEMBL8465634 | 0.82 | TAAR1 (0.55) | CHRM2CHRM1CHRM3TAAR1IDO1 | |
| SCHEMBL2091147 | 0.82 | ALDH1A1 (0.60) | CHRM2CHRM1CHRM3TAAR1IDO1 | |
| SCHEMBL29382328 | 0.82 | ALDH1A1 (0.60) | CHRM2CHRM1CHRM3TAAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| EP-4704846-A2 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4608829-A2 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-110256404-B | Diene compound with insecticidal activity, preparation and application thereof | 华东理工大学 | 2025-05-27 | — | — | CN | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-116672289-B | Leaf extract of white mustard and application thereof in preparing cosmetics | 西藏藏医药大学 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024229454-A2 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20240368151-A1 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-5180733-A | Antidepressants or nervous systen disorders | ABBOTT LABORATORIES (US) | 1993-01-19 | — | — | US | disclosed |
| EP-0461353-A1 | Biogenic amine uptake inhibitors | ABBOTT LABORATORIES (US) | 1991-12-18 | — | — | EP | disclosed |
| US-4647579-A | Circulation active novel substituted 4-hydroxy-benzopyrans | BAYER AKTIENGESELLSCHAFT (DE) | 1987-03-03 | — | — | US | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0158164-A2 | Substituted 4-hydroxy-benzopyrans, process for their preparation and their use in medicines | BAYER AG (DE) | 1985-10-16 | — | — | EP | disclosed |
| EP-0109679-B1 | PROCESS FOR THE SIMULTANEOUS PRODUCTION OF PHENYLACETATE ESTERS AND PHENYLACETALDEHYDES | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-08-14 | — | — | EP | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
| EP-0109679-A1 | Process for the simultaneous production of phenylacetate esters and phenylacetaldehydes | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4177197-A | Cyclization substrates and 7α-substituted 19-norsteroid derivatives | AKZONA INC. (US) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368151-A1 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | HTR2C, GRIN2C, ERG | CHRM2 199/4885CHRM1 367/4885CHRM3 222/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | CHRM2 221/4885CHRM1 337/4885CHRM3 272/4885 |
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | CHRM2 2577/4885CHRM1 2424/4885CHRM3 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.